Currently Active Clinical Trials
There is a great deal of interest in developing new and better treatments for MS, and a lot of current research ongoing. The group at UT is very active in working on new treatments, and always has several studies in progress. We currently have one study which is actively enrolling and others in the startup stage.
If you are interested in participating in any of these studies, please call Tanya Khan at 713 500-7045 for more information.
Ocrelizumab short treatment studyInvestigator: J. William Lindsey, MDTreatment being tested: testing the duration of treatment needed with ocrevusPurpose: Phase III study to determine if Ocrevus given early in MS has a long lasting benefit or if it needs to be given continuously. We currently keep people on Ocrevus for years, but there is evidence that is not necessary. The benefit from two years of treatment on ocrevus may be long lasting, and continued treatment with its long term effects on the immune system may not be necessary. Key inclusion criteria: relapsing MS with symptom onset in the last 3 years, never treated with ocrevus, briumvi, or kesimpta. Age 18 to 65. Status: enrolling
Epstein-Barr Virus & MSInvestigator: J. William Lindsey, M.D.EBV is a common virus which has been linked to MS in several different studies. Some people think that EBV may be one of the causes of MS. Dr. Lindsey is investigating the connection between EBV and MS. Our current interest is obtaining spinal fluid and blood from people with new onset of MS. We study these samples with RNA sequencing and hope to determine the target of the autoimmune attack in the brain.